0.77
+0(+0.00%)
Currency In USD
| Previous Close | 0.77 |
| Open | 0.78 |
| Day High | 0.8 |
| Day Low | 0.72 |
| 52-Week High | 4.94 |
| 52-Week Low | 0.58 |
| Volume | 73,617 |
| Average Volume | 1.14M |
| Market Cap | 2.83M |
| PE | -0.18 |
| EPS | -4.25 |
| Moving Average 50 Days | 1.04 |
| Moving Average 200 Days | 2.4 |
| Change | 0 |
If you invested $1000 in Shuttle Pharmaceuticals Holdings, Inc. (SHPH) since IPO date, it would be worth $2.5 as of December 26, 2024 at a share price of $0.771. Whereas If you bought $1000 worth of Shuttle Pharmaceuticals Holdings, Inc. (SHPH) shares 1 year ago, it would be worth $211.23 as of December 26, 2024 at a share price of $0.771.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
GlobeNewswire Inc.
Dec 19, 2024 2:00 PM GMT
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients trea
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
GlobeNewswire Inc.
Nov 26, 2024 2:00 PM GMT
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients trea
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Oct 30, 2024 1:05 AM GMT
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for can